// MedKitt — Potassium Disorders (Hyperkalemia & Hypokalemia) Management
// Initial Assessment → HyperK Severity → Severe HyperK Rx → K+ Elimination → HypoK Management → Periodic Paralysis
// 6 modules: Initial Assessment → HyperK Severity → Severe HyperK Rx → K+ Elimination → HypoK Management → Periodic Paralysis
// 24 nodes total.

import type { DecisionNode } from '../../models/types.js';
import type { Citation } from './neurosyphilis.js';

export const POTASSIUM_CRITICAL_ACTIONS = [
  { text: 'Calcium 3g IV (or CaCl 1g central) over 10 min for ECG changes - onset <5 min', nodeId: 'k-hyper-calcium' },
  { text: 'Regular insulin 5 units IV + D10W 500 mL over 4h (less hypoglycemia than D50W)', nodeId: 'k-hyper-insulin' },
  { text: 'Terbutaline 0.5 mg SQ preferred over albuterol (logistically superior)', nodeId: 'k-hyper-beta2' },
  { text: 'Isotonic bicarbonate (3 amp in 1L D5W) AS resuscitative fluid if bicarb <22', nodeId: 'k-hyper-bicarb' },
  { text: 'Diuretic + replace losses with LR - simple, scalable, effective kaliuresis', nodeId: 'k-hyper-step3' },
  { text: 'K+ <2.5 or life-threatening: KCl 5-10 mEq over 15-30 min with cardiac monitoring', nodeId: 'k-hypo-severe' },
  { text: 'Always check and correct magnesium - 50% of hypoK have concurrent hypoMg', nodeId: 'k-hypo-severe' },
  { text: 'HypoPP: oral KCl 1 mEq/kg (transcellular shift, NOT true depletion - avoid aggressive IV)', nodeId: 'k-hypopp-acute' },
  { text: 'AVOID normal saline in hyperkalemia (worsens K+ via chloride-bicarb exchange)', nodeId: 'k-hyper-step2' },
];

export const POTASSIUM_NODES: DecisionNode[] = [

  // =====================================================================
  // MODULE 1: INITIAL ASSESSMENT
  // =====================================================================

  {
    id: 'k-start',
    type: 'question',
    module: 1,
    title: 'Potassium Level',
    body: '[Potassium Disorders Steps Summary](#/info/k-summary) — stepwise management of hyperkalemia and hypokalemia.\n\nWhat is the serum potassium level?\n\nConfirm result with clinical context. Consider repeating if unexpected.',
    options: [
      {
        label: 'Hyperkalemia (K+ > 5.5 mEq/L)',
        next: 'k-hyper-ecg',
      },
      {
        label: 'Hypokalemia (K+ < 3.5 mEq/L)',
        next: 'k-hypo-assess',
      },
      {
        label: 'Borderline / Unexpected Result',
        next: 'k-pseudo',
      },
    ],
    summary: 'Route to hyperkalemia or hypokalemia pathway — repeat if unexpected, consider pseudohyperkalemia',
  },

  {
    id: 'k-pseudo',
    type: 'info',
    module: 1,
    title: 'Pseudohyperkalemia & Lab Verification',
    body: '**Rule out pseudohyperkalemia before treating:**\n\n\u2022 In vitro hemolysis (most common artifact) \u2014 repeat lab\n\u2022 Severe polycythemia (platelets >1M or WBC >50K) \u2014 use heparinized tube or POC\n\u2022 Prolonged tourniquet application or fist clenching\n\u2022 Delayed sample processing\n\n**Point-of-care testing** is generally accurate but cannot detect hemolysis.\n\nIf lab reports severe hyperkalemia but ECG is normal \u2192 consider pseudohyperkalemia and repeat the lab.',
    citation: [1, 7],
    next: 'k-start',
    summary: 'Rule out hemolysis, polycythemia, prolonged tourniquet — POC testing if severe polycythemia',
    skippable: true,
  },

  {
    id: 'k-hyper-ecg',
    type: 'info',
    module: 1,
    title: 'Check ECG Immediately',
    body: 'The **first response** to a lab report of hyperkalemia should be to look at telemetry and obtain an ECG.\n\n[Hyperkalemia ECG Findings](#/info/k-hyper-ecg-info) \u2014 progression by K+ level\n\n**If ECG shows hyperkalemia features** \u2192 confirms diagnosis, treat as severe.\n\n**If severe lab value but normal ECG** \u2192 consider pseudohyperkalemia, repeat lab.\n\nMost patients with hyperkalemia are **asymptomatic**, even with severe elevations.',
    images: [{ src: 'images/potassium/hyperkalemia-ecg.jpg', alt: 'ECG from a patient with K+ 8.2 mmol/L showing prominent peaked narrow T waves', caption: 'Hyperkalemia ECG (K⁺ 8.2 mmol/L) — peaked narrow T waves. Escalating findings: peaked T → PR prolongation → wide QRS → sine wave → PEA. (CC BY 4.0)' }],
    citation: [1, 5],
    next: 'k-hyper-severity',
    summary: 'First response: check ECG — features confirm diagnosis; normal ECG with severe lab = consider pseudohyperkalemia',
    safetyLevel: 'critical',
  },

  // =====================================================================
  // MODULE 2: HYPERK SEVERITY
  // =====================================================================

  {
    id: 'k-hyper-severity',
    type: 'question',
    module: 2,
    title: 'Hyperkalemia Severity',
    body: 'Classify severity based on potassium level, ECG changes, chronicity, and ongoing K+ release.\n\n**Severe hyperkalemia (KDIGO):**\n\u2022 K+ \u2265 6.5 mEq/L with ECG changes\n\u2022 K+ \u2265 6.0 mEq/L with rapid rise or ongoing release (TLS, rhabdo)\n\n**Chronic hyperkalemia** (e.g., dialysis patients) is better tolerated than acute.\n\n**Most dangerous ECG findings:** Bradycardia (RR 12.3), QRS widening (RR 4.7), junctional rhythm (RR 7.5).',
    citation: [1, 5, 7],
    options: [
      {
        label: 'Severe Hyperkalemia',
        description: 'K+ \u22656.5 + ECG changes, K+ \u22657.0, or ongoing K+ release',
        next: 'k-hyper-step1',
      },
      {
        label: 'Moderate Hyperkalemia',
        description: 'K+ 5.5-6.5, no ECG changes, hemodynamically stable',
        next: 'k-hyper-mod',
      },
    ],
    summary: 'Severe: K+ >=6.5 + ECG changes or rapid rise; bradycardia and QRS widening most dangerous findings',
  },

  {
    id: 'k-hyper-mod',
    type: 'info',
    module: 2,
    title: 'Moderate Hyperkalemia Management',
    body: '**[1] Treat definable causes:**\n\u2022 Discontinue offending medications and nephrotoxins\n\u2022 Establish euvolemia with adequate perfusion\n\u2022 Consider renal diet with limited K+ intake\n\n**[2] Gentle kaliuresis:**\n\u2022 [Furosemide](#/drug/furosemide) 40-80 mg IV \u2014 may be sufficient as sole diuretic\n\u2022 Replace urine volume with Lactated Ringers to maintain even fluid balance\n\nIf single diuretic fails \u2192 escalate to aggressive kaliuresis strategy.',
    citation: [1],
    treatment: {
      firstLine: {
        drug: 'Furosemide',
        dose: '40-80 mg',
        route: 'IV',
        frequency: 'Once, may repeat',
        duration: 'Until K+ normalizes',
        notes: 'May be sufficient as sole diuretic in moderate hyperkalemia with normal renal function',
      },
      monitoring: 'Monitor urine output, replace urine losses with LR to maintain euvolemia. Recheck K+ in 2-4 hours.',
    },
    next: 'k-hyper-step3',
    summary: 'Gentle kaliuresis with furosemide 40-80mg IV, replace urine volume with LR to maintain euvolemia',
  },

  // =====================================================================
  // MODULE 3: SEVERE HYPERK RX
  // =====================================================================

  {
    id: 'k-hyper-step1',
    type: 'info',
    module: 3,
    title: 'Step 1: Temporizing Measures',
    body: '**Start ALL temporizing measures simultaneously.**\n\nThese shift K+ into cells and stabilize the myocardium. They are **temporizing only** \u2014 K+ will return to baseline in 2-4 hours without definitive elimination therapy.\n\n**Three interventions:**\n1. IV Calcium \u2192 membrane stabilization\n2. Insulin + Dextrose \u2192 intracellular K+ shift\n3. Beta-2 agonist \u2192 intracellular K+ shift\n\n**Do NOT provide temporizing measures without definitive therapy.** This will temporarily improve the K+ but hyperkalemia will inevitably recur.',
    citation: [1, 2],
    next: 'k-hyper-calcium',
    summary: 'Start ALL three temporizing measures simultaneously — calcium, insulin/dextrose, beta-2 agonist',
    safetyLevel: 'critical',
  },

  {
    id: 'k-hyper-calcium',
    type: 'info',
    module: 3,
    title: 'IV Calcium \u2014 Membrane Stabilization',
    body: '**Indications:** ECG changes (especially bradycardia, QRS widening, conduction delays). Controversial for isolated peaked T-waves.\n\n**Dosing:**\n\u2022 Peripheral access: [Calcium Gluconate](#/drug/calcium-gluconate) **3 grams IV over 10 minutes**\n\u2022 Central access: [Calcium Chloride](#/drug/calcium-chloride) **1 gram IV over 10 minutes**\n\n**Duration:** 30-60 minutes only \u2014 may need to repeat 1-2 times.\n\nRapid IV calcium may cause flushing, nausea, abdominal discomfort.\n\n**Hyperkalemia is generally more dangerous than hypercalcemia** \u2014 err on the side of treating. Avoid pushing ionized calcium >3 mM.',
    citation: [1, 2, 11],
    summary: 'Calcium gluconate 3g IV over 10 min (peripheral) or CaCl 1g (central) — 30-60 min effect, may repeat',
    safetyLevel: 'critical',
    treatment: {
      firstLine: {
        drug: 'Calcium Gluconate',
        dose: '3 grams',
        route: 'IV over 10 minutes',
        frequency: 'May repeat 1-2 times',
        duration: '30-60 minutes effect',
        notes: 'Peripheral access. For central access use Calcium Chloride 1g IV.',
      },
      alternative: {
        drug: 'Calcium Chloride',
        dose: '1 gram',
        route: 'IV over 10 minutes (central line)',
        frequency: 'May repeat 1-2 times',
        duration: '30-60 minutes effect',
        notes: 'Requires central access due to extravasation risk',
      },
      monitoring: 'Repeat ECG. Avoid ionized calcium >3 mM. Watch for flushing, nausea, abdominal discomfort.',
    },
    next: 'k-hyper-insulin',
  },

  {
    id: 'k-hyper-insulin',
    type: 'info',
    module: 3,
    title: 'Insulin + Dextrose \u2014 K+ Shift',
    body: '**[Regular Insulin](#/drug/regular-insulin) 5 units IV bolus** (must be IV, NOT subcutaneous).\n\n**Dextrose co-administration:**\n\u2022 Glucose < 250 mg/dL \u2192 **D50W 2 ampules** (100 mL total) OR **D10W 500 mL over 4 hours** (preferred \u2014 less rebound hypoglycemia)\n\u2022 Glucose 180-250 \u2192 half-dose dextrose (25g)\n\u2022 Glucose > 250 \u2192 no dextrose needed\n\n**Monitor fingerstick glucose q1h for 4-6 hours.** If glucose < 70 \u2192 give additional dextrose.\n\n**Effect:** Onset 15-30 min. K+ reduction: 0.5-1.2 mEq/L. Duration: ~4 hours \u2014 plan for redosing or definitive therapy.',
    citation: [1, 3, 4],
    summary: 'Insulin 5 units IV + D10W 500mL over 4h preferred — monitor glucose q1h for 4-6h, K+ drops 0.5-1.2',
    safetyLevel: 'warning',
    treatment: {
      firstLine: {
        drug: 'Regular Insulin + Dextrose',
        dose: '5 units Regular Insulin + D10W 500 mL',
        route: 'IV bolus (insulin) + IV infusion (D10W)',
        frequency: 'Once, may redose in 4 hours',
        duration: '4 hours effect',
        notes: 'D10W over 4 hours preferred over D50W (less rebound hypoglycemia). Skip dextrose if glucose >250.',
      },
      alternative: {
        drug: 'Regular Insulin + D50W',
        dose: '5 units Regular Insulin + 2 ampules D50W (50g)',
        route: 'IV bolus (both)',
        frequency: 'Once, may redose in 4 hours',
        duration: '4 hours effect',
        notes: 'Higher risk of rebound hypoglycemia. Half-dose dextrose if glucose 180-250.',
      },
      monitoring: 'Fingerstick glucose q1h for 4-6 hours. Give additional dextrose if glucose <70.',
    },
    next: 'k-hyper-beta2',
  },

  {
    id: 'k-hyper-beta2',
    type: 'info',
    module: 3,
    title: 'Beta-2 Agonist \u2014 K+ Shift',
    body: '**Preferred:** [Terbutaline](#/drug/terbutaline) **0.5 mg SQ** \u2014 single injection, logistically superior.\n\n**Alternative:** [Albuterol](#/drug/albuterol-neb) **10-20 mg nebulized** (4-8 standard nebs back-to-back). Nearly always underdosed in practice \u2014 a single 2.5 mg neb is inadequate.\n\n**If hypotensive/bradycardic:** [Epinephrine](#/drug/epinephrine) infusion \u2014 treats both hyperkalemia AND hemodynamic instability simultaneously.\n\n**Effect:** Onset 5-30 min. K+ reduction: 0.5-1 mEq/L. Duration: 2-4 hours. Efficacy ~50% lower in ESRD.',
    citation: [1, 6],
    summary: 'Terbutaline 0.5mg SQ preferred over nebulized albuterol — single injection vs 4-8 nebs, similar efficacy',
    treatment: {
      firstLine: {
        drug: 'Terbutaline',
        dose: '0.5 mg',
        route: 'Subcutaneous',
        frequency: 'Once',
        duration: '2-4 hours effect',
        notes: 'Single injection, logistically superior to nebulized albuterol',
      },
      alternative: {
        drug: 'Albuterol',
        dose: '10-20 mg (4-8 standard nebs)',
        route: 'Nebulized back-to-back',
        frequency: 'Once',
        duration: '2-4 hours effect',
        notes: 'A single 2.5 mg neb is inadequate. Efficacy ~50% lower in ESRD.',
      },
      monitoring: 'Monitor heart rate. Watch for tremor, tachycardia. Onset 5-30 min.',
    },
    next: 'k-hyper-step2',
  },

  {
    id: 'k-hyper-step2',
    type: 'question',
    module: 3,
    title: 'Step 2: Volume Resuscitation',
    body: 'Assess volume status and serum bicarbonate to guide fluid choice.\n\n**Do NOT use normal saline** \u2014 high chloride content worsens hyperkalemia.\n\nIsotonic bicarbonate is the **preferred resuscitative fluid** for hyperkalemic patients with metabolic acidosis.',
    citation: [1, 8, 9],
    options: [
      {
        label: 'Bicarb < 22 mEq/L (metabolic acidosis)',
        description: 'Use isotonic bicarbonate for volume resuscitation',
        next: 'k-hyper-bicarb',
      },
      {
        label: 'Bicarb \u2265 22 mEq/L or euvolemic',
        description: 'Use LR or Plasmalyte if fluid needed. Proceed to kaliuresis.',
        next: 'k-hyper-step3',
      },
    ],
    summary: 'Do NOT use normal saline — high chloride worsens hyperK; isotonic bicarb preferred if acidotic',
    safetyLevel: 'warning',
  },

  {
    id: 'k-hyper-bicarb',
    type: 'info',
    module: 3,
    title: 'Isotonic Bicarbonate Resuscitation',
    body: '**Preparation:** 3 ampules NaHCO\u2083 in 1 liter D5W = **150 mM isotonic bicarbonate solution**.\n\n**Dosing:** 500-1000 mL/hour if severely hypovolemic. Target serum bicarb 24-28 mEq/L.\n\n**Isotonic bicarb lowers K+ three ways:**\n1. Dilution\n2. Shifting K+ into muscle cells\n3. Alkalosis promotes renal K+ excretion\n\n**Common mistake:** Giving isotonic bicarb at 100-150 mL/hr alongside another crystalloid. This prevents achieving the full benefit \u2014 use isotonic bicarb AS the resuscitative fluid.\n\n**AVOID hypertonic bicarbonate** (ampules alone) \u2014 proven ineffective in multiple RCTs. Osmotic shifts counteract the K-lowering effect.\n\nOnce bicarb > 24 and still hypovolemic \u2192 switch to LR for remaining volume.',
    citation: [1, 8, 9],
    treatment: {
      firstLine: {
        drug: 'Isotonic Sodium Bicarbonate',
        dose: '3 ampules NaHCO3 in 1 L D5W (150 mM solution)',
        route: 'IV infusion',
        frequency: '500-1000 mL/hour if severely hypovolemic',
        duration: 'Until serum bicarb 24-28 mEq/L',
        notes: 'Use AS the resuscitative fluid, not alongside other crystalloids. Switch to LR once bicarb >24.',
      },
      monitoring: 'Serum bicarbonate, K+, volume status. Avoid hypertonic bicarb ampules alone (proven ineffective).',
    },
    next: 'k-hyper-step3',
    summary: '3 amps NaHCO3 in 1L D5W AS the resuscitative fluid — hypertonic bicarb ampules alone are ineffective',
  },

  {
    id: 'k-hyper-step3',
    type: 'info',
    module: 3,
    title: 'Step 3: Kaliuresis (Diuretic Strategy)',
    body: 'Scale diuretic intensity to severity of hyperkalemia and renal function.\n\n**Normal renal function:**\n\u2022 [Furosemide](#/drug/furosemide) 60-160 mg IV alone may suffice\n\n**Moderate-severe renal dysfunction ("nephron bomb"):**\n\u2022 [Furosemide](#/drug/furosemide) 160-250 mg IV (or [Bumetanide](#/drug/bumetanide) 4-5 mg IV)\n\u2022 + [Chlorothiazide](#/drug/chlorothiazide) 500-1000 mg IV (or [Metolazone](#/drug/metolazone) 5-10 mg PO)\n\u2022 +/- [Acetazolamide](#/drug/acetazolamide) 250-1000 mg IV/PO\n\u2022 +/- [Fludrocortisone](#/drug/fludrocortisone) 0.2 mg PO (esp. patients on ACEi/ARB, tacrolimus)\n\n**Replace urine losses** with crystalloid:\n\u2022 Bicarb < 22 \u2192 isotonic bicarbonate\n\u2022 Bicarb \u2265 22 \u2192 Lactated Ringers\n\nIn life-threatening hyperK, **err on the side of excessive diuretic**. Large-volume diuresis is easily corrected with crystalloid.',
    citation: [1, 2],
    treatment: {
      firstLine: {
        drug: 'Furosemide + Chlorothiazide (Nephron Bomb)',
        dose: 'Furosemide 160-250 mg IV + Chlorothiazide 500-1000 mg IV',
        route: 'IV',
        frequency: 'Once, may repeat',
        duration: 'Until adequate urine output and K+ improving',
        notes: 'For moderate-severe renal dysfunction. Add Acetazolamide 250-1000 mg and/or Fludrocortisone 0.2 mg PO PRN.',
      },
      alternative: {
        drug: 'Furosemide (monotherapy)',
        dose: '60-160 mg',
        route: 'IV',
        frequency: 'Once, may repeat',
        duration: 'Until adequate urine output and K+ improving',
        notes: 'May suffice alone with normal renal function',
      },
      monitoring: 'Urine output, replace losses with LR (bicarb >22) or isotonic bicarb (bicarb <22). Check K+, Mg frequently.',
    },
    next: 'k-hyper-step3-response',
    summary: 'Scale diuretic to renal function — "nephron bomb" for moderate-severe CKD, replace urine losses with crystalloid',
  },

  {
    id: 'k-hyper-step3-response',
    type: 'question',
    module: 3,
    title: 'Assess Diuretic Response',
    body: 'Monitor urine output. If the patient produces urine, check potassium content.\n\nIf making urine but K+ not falling \u2192 consider adding [Fludrocortisone](#/drug/fludrocortisone) 0.2 mg PO.\n\nCheck electrolytes (including Mg) frequently and replete as needed.',
    citation: [1],
    options: [
      {
        label: 'Making urine \u2014 K+ improving',
        description: 'Continue kaliuresis, replace urine volume, monitor',
        next: 'k-hyper-step4',
      },
      {
        label: 'Not making urine \u2014 kaliuresis failed',
        description: 'Anuric despite diuretics \u2192 dialysis indicated',
        next: 'k-hyper-step5',
      },
    ],
    summary: 'Monitor urine output and K+ — add fludrocortisone if making urine but K+ not falling',
  },

  // =====================================================================
  // MODULE 4: K+ ELIMINATION
  // =====================================================================

  {
    id: 'k-hyper-step4',
    type: 'info',
    module: 4,
    title: 'Step 4: Potassium Binders',
    body: '[Lokelma (SZC)](#/drug/sodium-zirconium-cyclosilicate) **10 grams PO q8h**\n\nOnly **mildly effective** (~0.2 mM reduction at 4 hours, ~0.4 mM at 24 hours). Should NOT be relied upon as sole treatment.\n\nMay help **avoid or delay dialysis** in borderline cases.\n\n**Avoid Kayexalate** \u2014 antiquated, probably ineffective for acute hyperK, and can cause **colonic necrosis**.\n\nPatiromer is less effective than SZC (~0.23 mM at 7 hours). Only use if SZC unavailable.',
    citation: [1, 12, 13],
    treatment: {
      firstLine: {
        drug: 'Sodium Zirconium Cyclosilicate (Lokelma)',
        dose: '10 grams',
        route: 'PO',
        frequency: 'Every 8 hours',
        duration: 'Until K+ normalized or dialysis initiated',
        notes: 'Mildly effective (~0.2-0.4 mM reduction). Do NOT rely on as sole treatment. May delay dialysis.',
      },
      alternative: {
        drug: 'Patiromer',
        dose: '8.4 grams',
        route: 'PO',
        frequency: 'Daily',
        duration: 'Until K+ normalized',
        notes: 'Less effective than SZC. Only use if SZC unavailable. Avoid Kayexalate (colonic necrosis risk).',
      },
      monitoring: 'Recheck K+ in 4-6 hours. Do NOT delay dialysis if indicated.',
    },
    next: 'k-hyper-monitor',
    summary: 'SZC 10g PO q8h mildly effective — avoid Kayexalate (colonic necrosis risk), do not rely as sole treatment',
    safetyLevel: 'warning',
  },

  {
    id: 'k-hyper-step5',
    type: 'info',
    module: 4,
    title: 'Step 5: Dialysis',
    body: '**Indications for emergent dialysis:**\n1. Chronic hemodialysis patient (kaliuresis is futile)\n2. Failure of all other measures (anuric despite diuretic bomb, not a candidate for large-volume isotonic bicarb)\n\n**Do NOT delay dialysis** while hoping potassium binders will work.\n\nFor chronic HD patients, 5 grams of SZC daily on non-dialysis days may help reduce intradialytic hyperkalemia.',
    citation: [1],
    next: 'k-hyper-monitor',
    summary: 'Dialysis for chronic HD patients or anuric despite diuretic bomb — do not delay for binders',
    safetyLevel: 'critical',
  },

  {
    id: 'k-hyper-monitor',
    type: 'result',
    module: 4,
    title: 'Hyperkalemia Monitoring & Reassessment',
    body: '**Ongoing monitoring during acute hyperkalemia treatment.**\n\nRecheck K+ every 1-2 hours. Repeat ECG with any clinical change.\n\nInsulin K+ shift lasts ~4 hours \u2014 plan for redosing or definitive elimination.\n\nMonitor glucose q1h for 4-6 hours post-insulin. Check Mg, Ca, phosphorus frequently.\n\nReplace urine losses with appropriate crystalloid. Address underlying cause simultaneously.',
    recommendation: 'Recheck K+ every 1-2 hours during acute treatment. Repeat ECG with any clinical change. Insulin K+ shift lasts ~4 hours \u2014 plan for redosing or definitive elimination. Monitor glucose q1h for 4-6 hours post-insulin. Check Mg, Ca, phosphorus frequently. Replace urine losses with appropriate crystalloid. Address underlying cause simultaneously.',
    citation: [1, 2],
  },

  // =====================================================================
  // MODULE 5: HYPOK MANAGEMENT
  // =====================================================================

  {
    id: 'k-hypo-assess',
    type: 'question',
    module: 5,
    title: 'Hypokalemia Assessment',
    body: 'Check ECG for arrhythmia risk. [Hypokalemia ECG Findings](#/info/k-hypo-ecg-info)\n\nAssess for life-threatening features:\n\u2022 Arrhythmia (VT, TdP, new AF)\n\u2022 Respiratory failure\n\u2022 Paralysis or severe weakness',
    citation: [14, 15],
    options: [
      {
        label: 'Severe (K+ \u2264 2.5 or life-threatening features)',
        description: 'Arrhythmia, paralysis, respiratory failure, or K+ \u2264 2.5',
        next: 'k-hypo-severe',
      },
      {
        label: 'Mild-Moderate (K+ 2.5-3.5, stable)',
        description: 'No arrhythmia, hemodynamically stable',
        next: 'k-hypo-mild',
      },
      {
        label: 'Suspect Periodic Paralysis',
        description: 'Episodic weakness, triggers, family history',
        next: 'k-hypopp-assess',
      },
    ],
    summary: 'Check ECG for arrhythmia, assess for life-threatening features — arrhythmia, paralysis, respiratory failure',
  },

  {
    id: 'k-hypo-severe',
    type: 'info',
    module: 5,
    title: 'Severe Hypokalemia \u2014 IV Replacement',
    body: '[Potassium Chloride IV](#/drug/potassium-chloride-iv) **5-10 mEq over 15-30 minutes** with continuous cardiac monitoring.\n\nRepeat until hemodynamically stable, ECG changes resolve, and K+ > 3 mEq/L. Then:\n\u2022 20-40 mEq IV at up to 10 mEq/hr (peripheral)\n\u2022 Up to 20 mEq/hr (central line + cardiac monitoring)\n\n**Use glucose-free fluids** \u2014 glucose stimulates insulin and worsens intracellular K+ shift.\n\n**Always check and correct magnesium** \u2014 up to 50% of hypokalemic patients have concurrent hypoMg, which makes K+ repletion refractory.\n\nIf Mg < 2.0 \u2192 [Magnesium Sulfate](#/drug/magnesium-sulfate/hypomagnesemia) 2g IV over 1 hour.',
    citation: [14, 15, 16],
    treatment: {
      firstLine: {
        drug: 'Potassium Chloride IV',
        dose: '5-10 mEq',
        route: 'IV over 15-30 minutes',
        frequency: 'Repeat until K+ >3 mEq/L, then 20-40 mEq at 10 mEq/hr',
        duration: 'Until hemodynamically stable and ECG normalized',
        notes: 'Use glucose-free fluids. Up to 20 mEq/hr with central line. Peripheral max 10 mEq/hr.',
      },
      alternative: {
        drug: 'Magnesium Sulfate',
        dose: '2 grams',
        route: 'IV over 1 hour',
        frequency: 'Once',
        duration: 'If Mg <2.0',
        notes: 'Up to 50% of hypoK have concurrent hypoMg. Correct Mg for effective K+ repletion.',
      },
      monitoring: 'Continuous cardiac monitoring. Recheck K+ frequently. Always check and correct magnesium.',
    },
    next: 'k-hypo-workup',
    summary: 'KCl 5-10 mEq over 15-30 min IV with cardiac monitoring — always correct concurrent hypoMg (50% coexist)',
    safetyLevel: 'critical',
  },

  {
    id: 'k-hypo-mild',
    type: 'info',
    module: 5,
    title: 'Mild-Moderate Hypokalemia \u2014 Oral Replacement',
    body: '[Potassium Chloride Oral](#/drug/potassium-chloride-oral) **20-40 mEq PO**\n\nEach 20 mEq raises serum K+ ~0.2 mEq/L. KCl is the **preferred salt** (most causes of hypoK involve concurrent chloride losses).\n\nRecheck K+ in 2-4 hours.\n\n**Target K+ \u2265 4.0 mEq/L** \u2014 especially in heart failure and arrhythmia-prone patients.\n\n**Dietary potassium alone is INSUFFICIENT** \u2014 food K+ is coupled with phosphate, not chloride, and ineffective for replacing chloride-associated losses.\n\n**Always check magnesium** \u2014 hypoMg causes refractory hypokalemia via ROMK channel dysfunction.',
    citation: [14, 15, 16],
    treatment: {
      firstLine: {
        drug: 'Potassium Chloride Oral',
        dose: '20-40 mEq',
        route: 'PO',
        frequency: 'Once, may repeat',
        duration: 'Until K+ at target',
        notes: 'Each 20 mEq raises K+ ~0.2 mEq/L. KCl preferred over other potassium salts.',
      },
      monitoring: 'Recheck K+ in 2-4 hours. Target K+ >=4.0 mEq/L. Always check magnesium.',
    },
    next: 'k-hypo-workup',
    summary: 'KCl 20-40 mEq PO (each 20 mEq raises K+ ~0.2) — dietary potassium alone is insufficient',
  },

  {
    id: 'k-hypo-workup',
    type: 'info',
    module: 5,
    title: 'Hypokalemia Etiology',
    body: '**Common causes:**\n\u2022 Diuretics (thiazides > loops \u2014 0.6 vs 0.3 mEq/L decrease)\n\u2022 GI losses (vomiting, diarrhea, NG suction)\n\u2022 Refeeding syndrome\n\u2022 DKA treatment (insulin shifts K+ intracellularly)\n\u2022 Alkalosis\n\n**Workup:**\n\u2022 BMP, Mg, Phos\n\u2022 Urine K+ and Cl-\n\u2022 If urine K+ > 30 mEq/day \u2192 renal losses\n\u2022 If urine K+ < 25 mEq/day \u2192 extrarenal losses\n\n**Key:** Identify and treat the underlying cause in ALL patients.',
    citation: [14, 15],
    next: 'k-hypo-chronic',
    summary: 'Check urine K+ to differentiate renal vs extrarenal losses — diuretics, GI losses, DKA treatment common',
    skippable: true,
  },

  {
    id: 'k-hypo-chronic',
    type: 'result',
    module: 5,
    title: 'Long-Term Hypokalemia Management',
    body: '**Chronic K+ replacement and prevention strategy.**\n\nOral KCl 50-75 mEq/day for chronic replacement.\n\nFor diuretic-induced hypokalemia: low-salt diet, consider K-sparing diuretic, ACEi/ARB, or beta-blocker addition.\n\nLoop diuretics cause less hypoK than thiazides. Correct hypomagnesemia. Target K+ \u2265 4.0 mEq/L in heart failure patients.',
    recommendation: 'Oral KCl 50-75 mEq/day for chronic replacement (raises K+ ~0.14 mEq/L, enhanced with ACEi/ARB). For diuretic-induced: low-salt diet, consider K-sparing diuretic, ACEi/ARB, or beta-blocker addition. Loop diuretics cause less hypoK than thiazides. Monitor renal function and potassium regularly. Correct hypomagnesemia. Target K+ \u2265 4.0 mEq/L in heart failure patients.',
    citation: [14, 15, 16],
  },

  // =====================================================================
  // MODULE 6: PERIODIC PARALYSIS
  // =====================================================================

  {
    id: 'k-hypopp-assess',
    type: 'question',
    module: 6,
    title: 'Periodic Paralysis Assessment',
    body: '**Hypokalemic Periodic Paralysis (HypoPP)**\n\nEpisodic flaccid paralysis, **proximal > distal**, with normal-to-decreased reflexes. Lasting minutes to days with spontaneous recovery.\n\n**Triggers:** Rest after strenuous exercise, carbohydrate-rich evening meals (morning attacks), stress, cold, high sodium intake, corticosteroids, alcohol\n\n**KEY DISTINCTION:** Hypokalemia in HypoPP is **transcellular redistribution, NOT true body K+ depletion**. This fundamentally changes treatment.\n\n**Genetics:** CACNA1 (calcium channel) or SCN4A (sodium channel) mutations.',
    citation: [17, 18],
    options: [
      {
        label: 'Confirmed/Suspected HypoPP \u2014 Treat Attack',
        description: 'Episodic weakness with triggers, family history, or prior episodes',
        next: 'k-hypopp-acute',
      },
      {
        label: 'Not Periodic Paralysis',
        description: 'Proceed to standard hypokalemia management',
        next: 'k-hypo-severe',
      },
    ],
    summary: 'Episodic flaccid paralysis with triggers — transcellular redistribution, NOT true depletion',
  },

  {
    id: 'k-hypopp-acute',
    type: 'info',
    module: 6,
    title: 'HypoPP: Acute Attack Management',
    body: '**CRITICAL: This is NOT true K+ depletion \u2014 aggressive replacement causes dangerous rebound hyperkalemia.**\n\n[Potassium Chloride Oral](#/drug/potassium-chloride-oral) **1 mEq/kg oral** (~60 mEq for 60 kg patient)\n\u2022 Use **immediate-release or liquid** formulation ONLY\n\u2022 **AVOID slow-release** KCl \u2014 too slow and unpredictable\n\u2022 If no improvement in 30 min \u2192 0.3 mEq/kg additional dose\n\u2022 Monitor K+ every 30 minutes\n\n**For severe attacks requiring IV:**\n\u2022 Max rate 0.3 mEq/kg/hr with continuous cardiac monitoring\n\n**AVOID:**\n\u2022 Glucose-containing fluids (worsens intracellular shift)\n\u2022 Corticosteroids (known trigger)\n\u2022 Aggressive IV KCl (rebound hyperkalemia)\n\n**Resolution of weakness may lag behind K+ normalization.**',
    citation: [17, 18],
    calculatorLinks: [{ id: 'weight-dose', label: 'Weight-Based Calculator' }],
    treatment: {
      firstLine: {
        drug: 'Potassium Chloride Oral (immediate-release)',
        dose: '1 mEq/kg (~60 mEq for 60 kg patient)',
        route: 'PO (immediate-release or liquid only)',
        frequency: 'Once, may add 0.3 mEq/kg if no improvement in 30 min',
        duration: 'Until weakness resolves',
        notes: 'AVOID slow-release KCl. This is transcellular shift, NOT true depletion.',
      },
      alternative: {
        drug: 'Potassium Chloride IV (severe attacks)',
        dose: 'Max 0.3 mEq/kg/hr',
        route: 'IV with continuous cardiac monitoring',
        frequency: 'Continuous infusion',
        duration: 'Until clinical improvement',
        notes: 'Avoid aggressive IV replacement - risk of rebound hyperkalemia.',
      },
      monitoring: 'K+ every 30 minutes. Avoid glucose-containing fluids and corticosteroids. Weakness may lag K+ normalization.',
    },
    next: 'k-hypopp-prevent',
    summary: 'Oral KCl 1 mEq/kg immediate-release ONLY — avoid aggressive IV (rebound hyperK), avoid glucose/steroids',
    safetyLevel: 'critical',
  },

  {
    id: 'k-hypopp-prevent',
    type: 'result',
    module: 6,
    title: 'HypoPP: Prevention & Long-Term',
    body: '**Long-term prevention of hypokalemic periodic paralysis attacks.**\n\nTrigger avoidance: low sodium, low carbohydrate diet, avoid steroids/cold/stress/alcohol.\n\nDaily oral KCl 10-20 mEq TID (especially nocturnal dose for morning attacks).\n\nAcetazolamide is first-line pharmacologic prevention. If intolerant: K-sparing diuretics (triamterene, spironolactone, eplerenone).\n\nGenetic counseling: CACNA1 or SCN4A testing for family planning.',
    recommendation: 'Trigger avoidance: low sodium, low carbohydrate diet, avoid steroids/cold/stress/alcohol. Daily oral KCl 10-20 mEq TID (especially nocturnal dose for morning attacks). Acetazolamide is first-line pharmacologic prevention (mechanism uncertain \u2014 may involve systemic acidosis reducing attack susceptibility). If intolerant: K-sparing diuretics (triamterene, spironolactone, eplerenone). Magnesium supplementation may enhance renal K+ retention. Anesthetic precautions: strict K+ control, avoid glucose/salt loads, maintain temperature and acid-base balance. Genetic counseling: CACNA1 or SCN4A testing for family planning.',
    citation: [17, 18],
  },

];

export const POTASSIUM_NODE_COUNT = POTASSIUM_NODES.length;

// -------------------------------------------------------------------
// Module Labels (for progress indicator)
// -------------------------------------------------------------------

export const POTASSIUM_MODULE_LABELS = [
  'Initial Assessment',
  'HyperK Severity',
  'Severe HyperK Rx',
  'K+ Elimination',
  'HypoK Management',
  'Periodic Paralysis',
];

// -------------------------------------------------------------------
// Evidence Citations
// -------------------------------------------------------------------

export const POTASSIUM_CITATIONS: Citation[] = [
  { num: 1, text: 'Palmer BF, Clegg DJ. Hyperkalemia treatment standard. Nephrol Dial Transplant. 2024;39(7):1097-1104.' },
  { num: 2, text: 'Rossignol P, et al. Emergency management of severe hyperkalemia. Pharmacol Res. 2016;113(Pt A):585-591.' },
  { num: 3, text: 'Moussavi K, et al. Management of Hyperkalemia With Insulin and Glucose. J Emerg Med. 2019;57(1):36-42.' },
  { num: 4, text: 'Harel Z, Kamel KS. Optimal Dose of Intravenous Insulin for Hyperkalemia. PLoS One. 2016;11(5):e0154963.' },
  { num: 5, text: 'Durfey N, et al. Severe Hyperkalemia: Can the ECG Risk Stratify for Short-term Adverse Events? West J Emerg Med. 2017;18(5):963-971.' },
  { num: 6, text: 'Sowinski KM, et al. Subcutaneous terbutaline use in CKD to reduce potassium. Am J Kidney Dis. 2005;45(6):1040-5.' },
  { num: 7, text: 'Lindner G, et al. Acute hyperkalemia in the emergency department. Eur J Emerg Med. 2020;27(5):329-337.' },
  { num: 8, text: 'Weisberg LS. Management of severe hyperkalemia. Crit Care Med. 2008;36(12):3246-51.' },
  { num: 9, text: 'O\'Malley CM, et al. A randomized comparison of lactated Ringer\'s and 0.9% NaCl during renal transplantation. Anesth Analg. 2005;100(5):1518-24.' },
  { num: 10, text: 'Palmer BF, Clegg DJ. Diagnosis and Treatment of Hyperkalemia. Cleve Clin J Med. 2017;84(12):934-942.' },
  { num: 11, text: 'Gupta AA, et al. Dispelling myths and misconceptions about treatment of acute hyperkalemia. Am J Emerg Med. 2022;52:85-91.' },
  { num: 12, text: 'Sterns RH, et al. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010;21(5):733-5.' },
  { num: 13, text: 'Long B, et al. Controversies in Management of Hyperkalemia. J Emerg Med. 2018;55(2):192-205.' },
  { num: 14, text: 'Kim MJ, et al. Potassium Disorders: Hypokalemia and Hyperkalemia. Am Fam Physician. 2023;107(1):59-70.' },
  { num: 15, text: 'Gennari FJ. Hypokalemia. N Engl J Med. 1998;339(7):451-8.' },
  { num: 16, text: 'Ferreira JP, et al. Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(22):2836-2850.' },
  { num: 17, text: 'Statland JM, et al. Review of the Diagnosis and Treatment of Periodic Paralysis. Muscle Nerve. 2018;57(4):522-530.' },
  { num: 18, text: 'Weber F, Lehmann-Horn F. Hypokalemic Periodic Paralysis. GeneReviews. Updated 2018.' },
];

// -------------------------------------------------------------------
// Clinical Notes (for reference table)
// -------------------------------------------------------------------

export const POTASSIUM_CLINICAL_NOTES: string[] = [
  'Regular insulin 5 units IV (not 10) with mandatory dextrose reduces hypoglycemia from 15-20% to <5% while maintaining similar K-lowering effect.',
  'Terbutaline 0.5 mg SQ is logistically superior to nebulized albuterol \u2014 single injection vs. 4-8 back-to-back nebs with similar efficacy.',
  'Normal saline worsens hyperkalemia via renal tubular chloride-bicarbonate exchange. Use LR or Plasmalyte.',
  'Kayexalate has NO role in acute hyperkalemia management. Risk of colonic necrosis supersedes any theoretical benefit.',
  'ECG sensitivity for peaked T-waves in hyperkalemia is only ~34%. Never rule out dangerous hyperkalemia based on normal ECG.',
  'Always check and correct magnesium in hypokalemia \u2014 up to 50% have concurrent hypoMg which makes K+ repletion refractory.',
  'Hypokalemic Periodic Paralysis involves transcellular K+ redistribution \u2014 NOT true depletion. Aggressive IV repletion risks dangerous rebound hyperkalemia.',
  'IV KCl rates >10 mEq/hr require central venous access and continuous cardiac monitoring.',
  'Glucose-containing IV fluids worsen hypokalemia by stimulating insulin release and driving K+ intracellularly.',
  'Fludrocortisone 0.2 mg PO is underutilized for hyperK in patients on ACEi/ARB or tacrolimus \u2014 replaces suppressed mineralocorticoid effect.',
  'Isotonic bicarbonate (150 mM) works for hyperK with metabolic acidosis. Hypertonic bicarbonate ampules are proven ineffective in multiple RCTs.',
  'For life-threatening hyperkalemia, err on excessive diuretic \u2014 large-volume diuresis is easily corrected with crystalloid; inadequate diuretic may require dialysis.',
];
